222 related articles for article (PubMed ID: 24787972)
1. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.
Giannatempo P; Alessi A; Miceli R; Raggi D; Farè E; Nicolai N; Serafini G; Padovano B; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Mariani L; Gianni AM; Sonpavde G; Salvioni R; Necchi A; Crippa F
Clin Genitourin Cancer; 2014 Dec; 12(6):433-9. PubMed ID: 24787972
[TBL] [Abstract][Full Text] [Related]
2. [
Kollberg P; Almquist H; Bläckberg M; Cwikiel M; Gudjonsson S; Lyttkens K; Patschan O; Liedberg F
Scand J Urol; 2017 Aug; 51(4):308-313. PubMed ID: 28532260
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer.
Schrier BP; Peters M; Barentsz JO; Witjes JA
Eur Urol; 2006 Apr; 49(4):698-703. PubMed ID: 16464531
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
Sternberg CN; de Mulder PH; Schornagel JH; Théodore C; Fossa SD; van Oosterom AT; Witjes F; Spina M; van Groeningen CJ; de Balincourt C; Collette L;
J Clin Oncol; 2001 May; 19(10):2638-46. PubMed ID: 11352955
[TBL] [Abstract][Full Text] [Related]
6. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy.
Liu IJ; Lai YH; Espiritu JI; Segall GM; Srinivas S; Nino-Murcia M; Terris MK
Urol Int; 2006; 77(1):69-75. PubMed ID: 16825819
[TBL] [Abstract][Full Text] [Related]
8. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
10. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
11. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D
Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
Roberts JT; von der Maase H; Sengeløv L; Conte PF; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
Ann Oncol; 2006 May; 17 Suppl 5():v118-22. PubMed ID: 16807438
[TBL] [Abstract][Full Text] [Related]
14. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
16. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
[TBL] [Abstract][Full Text] [Related]
17. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
[TBL] [Abstract][Full Text] [Related]
18. Platinum-based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract.
Lerner SE; Blute ML; Richardson RL; Zincke H
Mayo Clin Proc; 1996 Oct; 71(10):945-50. PubMed ID: 8820768
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.
Correa-Gallego C; Gavane S; Grewal R; Cercek A; Klimstra DS; Gewirtz AN; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N; D'Angelica MI
HPB (Oxford); 2015 Jul; 17(7):644-50. PubMed ID: 26010778
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
